Dr. Reddy’s Laboratories announced that its contract research, development, and manufacturing organization (CRDMO) arm, Aurigene Pharmaceutical Services Limited, has inaugurated a new biologics facility spanning 70,000 sq ft in Genome Valley, Hyderabad. The facility aims to serve customers with process and analytical development, as well as small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements.
According to Dr. Reddy's, the process and analytical development laboratories are now operational, and the manufacturing capacity commissioning will be completed later in 2024. The new facility complements the company’s current discovery capabilities and infrastructure, focusing primarily on recombinant proteins, including mAbs, bi- and multi-specifics, immune-fusion molecules, antibody-drug conjugates, and other complex proteins.
This new facility enhances Aurigene’s end-to-end service offering, providing solutions from discovery through large-scale commercial manufacturing from three closely located campuses (discovery, process development, and clinical manufacture and large-scale commercial manufacture), ensuring seamless delivery from "concept to commercial".
The newly opened facility will provide robust, compliant, and economically viable cell lines, process development solutions, and supporting analytical methods to help customers enter and progress through clinical development rapidly.
Dr. Reddy’s highlighted that the opening of this latest facility is one of multiple strategic initiatives that Aurigene is implementing to support rapid growth in both the small molecule and biologics spaces, as illustrated by recent announcements related to AI/ML-led drug discovery in small molecules and a collaboration with Vipergen, a DNA-encoded library (DEL) technologies service provider.
Aurigene CEO Akhil Ravi expressed that the addition of new capacity and capabilities will enable Augiene to efficiently serve global customers and support the development of innovative medicine.